{"id":8852,"date":"2026-11-05T15:19:55","date_gmt":"2026-11-05T14:19:55","guid":{"rendered":"https:\/\/leyton.com\/us\/?post_type=article&p=8852"},"modified":"2026-11-05T15:25:29","modified_gmt":"2026-11-05T14:25:29","slug":"how-rd-tax-credits-strengthen-a-life-science-companys-valuation","status":"publish","type":"article","link":"https:\/\/leyton.com\/us\/insights\/articles\/how-rd-tax-credits-strengthen-a-life-science-companys-valuation\/","title":{"rendered":"How R&D Tax Credits Strengthen a Life Science Company’s Valuation"},"content":{"rendered":"\n

Introduction<\/h2>\n\n\n\n

Life science companies spend years, and often hundreds of millions of dollars, before a product earns revenue. Investors know the math: long timelines, binary clinical outcomes, and heavy capital needs. Anything that lowers the real cost of R&D, extends runway, or signals financial discipline can change how a company’s valuation. US federal and state R&D tax credits<\/a><\/strong> can do all three, but only if founders understand which credits produce cash and which simply sit on the balance sheet.<\/p>\n\n\n\n

The key distinction: cash-generating vs. carry-forward credits<\/h2>\n\n\n\n

The federal R&D credit under IRC Section 41 is non-refundable<\/strong> against income tax. A pre-revenue company with no taxable income can generate the credit, but it can’t collect it. Unused credits carry forward for up to 20 years, which has little value for a company that may not be profitable for a decade, if ever.<\/p>\n\n\n\n

This is why investors often assign little value to accumulated credits sitting on a balance sheet. The valuation case rests on credits that convert to cash within a realistic funding horizon. Two routes do this.<\/p>\n\n\n\n

Route 1: The federal payroll tax offset<\/h3>\n\n\n\n

Qualified small businesses can elect to apply up to $500,000 per year<\/strong> of their federal R&D credit against employer payroll taxes instead of income tax. To qualify, a company generally must have:<\/p>\n\n\n\n

    \n
  • Gross receipts under $5 million in the current year<\/li>\n\n\n\n
  • No gross receipts in any year before the five-year period ending with the current year<\/li>\n<\/ul>\n\n\n\n
    <\/div>\n\n\n\n

    Technically the credit remains non-refundable, but the effect on cash is real: the company keeps payroll tax dollars it would otherwise have sent to the IRS. For a venture-backed biotech with a lab full of scientists on payroll, that can mean up to $500K a year of retained cash, modeled as a recurring reduction in net burn. The limit is that the offset is capped by the company’s actual payroll tax liability, so very lean, contractor-heavy companies may not be able to use the full amount.<\/p>\n\n\n\n

    Route 2: State credits that are refundable or transferable<\/h3>\n\n\n\n

    State programs vary widely, and some are more cash-friendly than the federal credit. Depending on the state, a company may be able to:<\/p>\n\n\n\n

      \n
    • Receive a cash refund<\/strong> of the credit<\/li>\n\n\n\n
    • Sell or transfer<\/strong> the credit to a third party for cash<\/li>\n\n\n\n
    • Exchange<\/strong> the credit with the state at a discount<\/li>\n<\/ul>\n\n\n\n
      <\/div>\n\n\n\n

      New Jersey’s technology business tax certificate transfer program, Pennsylvania’s credit assignment process, and Connecticut’s cash exchange for R&D credits are well-known examples. Many other states offer only non-refundable carry-forwards, so state selection and site location can materially affect the economics.<\/p>\n\n\n\n

      How cash-generating credits extend runway and reduce dilution<\/h2>\n\n\n\n

      When a credit converts to cash, it works like non-dilutive capital:<\/p>\n\n\n\n

        \n
      • Longer runway.<\/strong> Recurring payroll offsets and state refunds reduce net burn, which can add months to the cash horizon and help the company reach a clinical or regulatory milestone before its next raise.<\/li>\n\n\n\n
      • Less dilution.<\/strong> Raising a smaller round, or raising later at a higher valuation, leaves more of the company with founders and early investors.<\/li>\n\n\n\n
      • Better negotiating leverage.<\/strong> A company that isn’t forced to raise urgently gets better terms.<\/li>\n<\/ul>\n\n\n\n
        <\/div>\n\n\n\n

        Investors value what they can model<\/h2>\n\n\n\n

        Sophisticated investors will test whether credits belong in the financial model:<\/p>\n\n\n\n

          \n
        • Does the credit produce cash within 12 to 24 months?<\/strong> If so, it reduces net burn and belongs in the base case.<\/li>\n\n\n\n
        • Is it a deferred tax asset?<\/strong> If it only offsets future taxable income, investors will discount it heavily or ignore it.<\/li>\n<\/ul>\n\n\n\n
          <\/div>\n\n\n\n

          The credit is a mechanical benefit, not a valuation multiple. It scales with spending, is capped and time-limited, and carries policy and audit risk, so capitalizing it at a multiple invites skepticism. Its real value shows up in capital efficiency: a lower net cash need, a smaller funding gap, and less dilution in DCF or rNPV models.<\/p>\n\n\n\n

          How to present credits to investors<\/h2>\n\n\n\n

          Many founders describe R&D credits as a pot of value: “our credits are worth $X.” A stronger approach is to translate the credit into metrics investors already use: net burn, runway, and dilution.<\/p>\n\n\n\n

          Consider a company with $20M in cash and a $10M annual burn, or 24 months of runway. A $500K payroll tax offset reduces net burn to $9.5M, stretching runway to about 25 months. On the next raise, the company needs roughly $500K less. On a $10M round at a $40M pre-money valuation, that’s about 0.8 points less dilution. The numbers are hypothetical, but the story is modest, credible, and verifiable in the model.<\/p>\n\n\n\n

          So instead of “our credits add $X of value,” say “after credits, our net burn is $X, which extends runway to Y months and reduces the size of our next round by Z.” Show cash-generating credits as a reduction in burn, and keep carry-forward credits as a separate memo line, excluded from runway.<\/p>\n\n\n\n

          The right way to model these credits depends on your payroll profile, your state footprint, and how your next round is structured. If you’d like to see how this would look in your own burn schedule, get in touch.<\/p>\n\n\n\n

          The Section 174 factor<\/h2>\n\n\n\n

          For tax years 2022 through 2024, Section 174 required companies to capitalize and amortize R&D expenses over five years, which created taxable income even for companies with large economic losses and hurt cash flow. <\/p>\n\n\n\n

          Legislation passed in 2025 restored immediate expensing of domestic R&D for tax years beginning after December 31, 2024, with transition relief available for earlier years, including an option for qualifying small businesses to apply the change retroactively. <\/p>\n\n\n\n

          Founders should confirm how this affects their own filings, since it changes both the cash tax picture and how the credit interacts with deductions.<\/p>\n\n\n\n

          A well-managed claim signals operational maturity<\/h2>\n\n\n\n

          Life science investors look beyond the science. A robust credit process shows that a company:<\/p>\n\n\n\n

            \n
          • Tracks R&D spend by project, the same discipline needed for grant reporting and clinical budgeting<\/li>\n\n\n\n
          • Documents technical uncertainty and experimentation, consistent with good scientific recordkeeping<\/li>\n\n\n\n
          • Has finance and science teams working from the same information<\/li>\n<\/ul>\n\n\n\n
            <\/div>\n\n\n\n

            In diligence, clean and defensible claims reduce perceived risk. An aggressive or poorly documented claim can create a contingent tax liability that investors will deduct from the price or protect against through warranties and indemnities. Quality matters more than size.<\/p>\n\n\n\n

            Exit and change-of-control considerations<\/h2>\n\n\n\n

            Accumulated credits can add value in an acquisition, but IRC Section 382 limits how much of a company’s pre-acquisition credits and losses a buyer can use after a change of ownership. Companies that have raised multiple rounds may already have triggered limitations. This is an exit-value consideration rather than a runway benefit, and acquirers will typically assign it modest value.<\/p>\n\n\n\n

            Pitfalls that can erode value<\/h2>\n\n\n\n
              \n
            • Over-claiming.<\/strong> Including non-qualifying costs invites audits and damages trust with investors.<\/li>\n\n\n\n
            • Weak documentation.<\/strong> Claims should rest on contemporaneous records, not reconstructions.<\/li>\n\n\n\n
            • Assuming all credits are cash.<\/strong> Counting carry-forward credits as runway overstates liquidity.<\/li>\n\n\n\n
            • Valuing credits at a multiple.<\/strong> Credits scale with spending and are capped, so investors will not capitalize them.<\/li>\n\n\n\n
            • Ignoring state variation.<\/strong> Refundability, caps, and eligibility differ widely by state.<\/li>\n\n\n\n
            • Assuming permanence.<\/strong> Federal and state rules change frequently, so models should flag policy risk.<\/li>\n<\/ul>\n\n\n\n
              <\/div>\n\n\n\n

              Practical steps for founders<\/h2>\n\n\n\n
                \n
              1. Map qualifying activities early, including preclinical work, formulation, assay development, and process optimization.<\/li>\n\n\n\n
              2. Build tracking into normal operations with timesheets, project codes, and lab records.<\/li>\n\n\n\n
              3. Confirm payroll tax offset eligibility each year, including the gross receipts tests.<\/li>\n\n\n\n
              4. Evaluate states for refundable or transferable credits when choosing where to locate R&D.<\/li>\n\n\n\n
              5. Show credits in the model with separate lines for cash-generating and carry-forward amounts.<\/li>\n\n\n\n
              6. Present credits as net burn, runway, and dilution, not as a standalone value.<\/li>\n\n\n\n
              7. Prepare a diligence-ready file with methodology, calculations, and prior-year results.<\/li>\n\n\n\n
              8. Work with advisers who understand both the tax rules and life science R&D.<\/li>\n<\/ol>\n\n\n\n
                <\/div>\n\n\n\n

                Conclusion<\/h2>\n\n\n\n

                US R&D credits won’t make a weak asset investable, but for a strong one they can meaningfully lower net burn, extend runway, and reduce dilution, provided the company structures its claims to generate cash rather than only accumulate carry-forwards. <\/p>\n\n\n\n

                Companies that plan for the payroll offset and state incentives from the start, and document claims rigorously, present investors with a more capital-efficient and lower-risk story. That is what ultimately supports a stronger valuation.<\/p>\n\n\n\n\n","protected":false},"excerpt":{"rendered":"

                Introduction Life science companies spend years, and often hundreds of millions of dollars, before a product earns revenue. Investors know the math: long timelines, binary clinical outcomes, and heavy capital needs. Anything that lowers the real cost of R&D, extends runway, or signals financial discipline can change how a company’s valuation. US federal and state […]<\/p>\n","protected":false},"author":72,"featured_media":8855,"menu_order":0,"comment_status":"open","ping_status":"open","template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[289,75],"tags":[173,115],"expertise":[370],"class_list":["post-8852","article","type-article","status-publish","format-standard","has-post-thumbnail","hentry","category-life-sciences-en","category-rd-tax-credit-en","tag-life-sciences-en","tag-rd-tax-credit-en","expertise-innovation-funding-incentives"],"acf":[],"yoast_head":"\nHow R&D Tax Credits Strengthen a Life Science Company's Valuation - Leyton United States<\/title>\n<meta name=\"description\" content=\"Discover how cash-generating R&D tax credits extend runway, reduce dilution, and strengthen a life science company's valuation.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/leyton.com\/us\/insights\/articles\/how-rd-tax-credits-strengthen-a-life-science-companys-valuation\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"How R&D Tax Credits Strengthen a Life Science Company's Valuation\" \/>\n<meta property=\"og:description\" content=\"Discover how cash-generating R&D tax credits extend runway, reduce dilution, and strengthen a life science company's valuation.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/leyton.com\/us\/insights\/articles\/how-rd-tax-credits-strengthen-a-life-science-companys-valuation\/\" \/>\n<meta property=\"og:site_name\" content=\"Leyton\" \/>\n<meta property=\"article:modified_time\" content=\"2026-11-05T14:25:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/leyton.com\/wp-content\/blogs.dir\/4\/files\/2026\/11\/USA-Website-inside-pictures-92.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"655\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/leyton.com\\\/us\\\/insights\\\/articles\\\/how-rd-tax-credits-strengthen-a-life-science-companys-valuation\\\/\",\"url\":\"https:\\\/\\\/leyton.com\\\/us\\\/insights\\\/articles\\\/how-rd-tax-credits-strengthen-a-life-science-companys-valuation\\\/\",\"name\":\"How R&D Tax Credits Strengthen a Life Science Company's Valuation - Leyton United States\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/leyton.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/leyton.com\\\/us\\\/insights\\\/articles\\\/how-rd-tax-credits-strengthen-a-life-science-companys-valuation\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/leyton.com\\\/us\\\/insights\\\/articles\\\/how-rd-tax-credits-strengthen-a-life-science-companys-valuation\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/leyton.com\\\/wp-content\\\/blogs.dir\\\/4\\\/files\\\/2026\\\/11\\\/USA-Website-inside-pictures-92.png\",\"datePublished\":\"2026-11-05T14:19:55+00:00\",\"dateModified\":\"2026-11-05T14:25:29+00:00\",\"description\":\"Discover how cash-generating R&D tax credits extend runway, reduce dilution, and strengthen a life science company's valuation.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/leyton.com\\\/us\\\/insights\\\/articles\\\/how-rd-tax-credits-strengthen-a-life-science-companys-valuation\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/leyton.com\\\/us\\\/insights\\\/articles\\\/how-rd-tax-credits-strengthen-a-life-science-companys-valuation\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/leyton.com\\\/us\\\/insights\\\/articles\\\/how-rd-tax-credits-strengthen-a-life-science-companys-valuation\\\/#primaryimage\",\"url\":\"https:\\\/\\\/leyton.com\\\/wp-content\\\/blogs.dir\\\/4\\\/files\\\/2026\\\/11\\\/USA-Website-inside-pictures-92.png\",\"contentUrl\":\"https:\\\/\\\/leyton.com\\\/wp-content\\\/blogs.dir\\\/4\\\/files\\\/2026\\\/11\\\/USA-Website-inside-pictures-92.png\",\"width\":1920,\"height\":655,\"caption\":\"valuation\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/leyton.com\\\/us\\\/insights\\\/articles\\\/how-rd-tax-credits-strengthen-a-life-science-companys-valuation\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/leyton.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"How R&D Tax Credits Strengthen a Life Science Company’s Valuation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/leyton.com\\\/#website\",\"url\":\"https:\\\/\\\/leyton.com\\\/\",\"name\":\"Leyton\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/leyton.com\\\/us\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/leyton.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/leyton.com\\\/us\\\/#organization\",\"name\":\"Leyton\",\"url\":\"https:\\\/\\\/leyton.com\\\/us\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/leyton.com\\\/us\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/leyton.com\\\/wp-content\\\/blogs.dir\\\/4\\\/files\\\/2026\\\/01\\\/logo.svg\",\"contentUrl\":\"https:\\\/\\\/leyton.com\\\/wp-content\\\/blogs.dir\\\/4\\\/files\\\/2026\\\/01\\\/logo.svg\",\"width\":108,\"height\":44,\"caption\":\"Leyton\"},\"image\":{\"@id\":\"https:\\\/\\\/leyton.com\\\/us\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"How R&D Tax Credits Strengthen a Life Science Company's Valuation - Leyton United States","description":"Discover how cash-generating R&D tax credits extend runway, reduce dilution, and strengthen a life science company's valuation.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/leyton.com\/us\/insights\/articles\/how-rd-tax-credits-strengthen-a-life-science-companys-valuation\/","og_locale":"en_US","og_type":"article","og_title":"How R&D Tax Credits Strengthen a Life Science Company's Valuation","og_description":"Discover how cash-generating R&D tax credits extend runway, reduce dilution, and strengthen a life science company's valuation.","og_url":"https:\/\/leyton.com\/us\/insights\/articles\/how-rd-tax-credits-strengthen-a-life-science-companys-valuation\/","og_site_name":"Leyton","article_modified_time":"2026-11-05T14:25:29+00:00","og_image":[{"width":1920,"height":655,"url":"https:\/\/leyton.com\/wp-content\/blogs.dir\/4\/files\/2026\/11\/USA-Website-inside-pictures-92.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/leyton.com\/us\/insights\/articles\/how-rd-tax-credits-strengthen-a-life-science-companys-valuation\/","url":"https:\/\/leyton.com\/us\/insights\/articles\/how-rd-tax-credits-strengthen-a-life-science-companys-valuation\/","name":"How R&D Tax Credits Strengthen a Life Science Company's Valuation - Leyton United States","isPartOf":{"@id":"https:\/\/leyton.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/leyton.com\/us\/insights\/articles\/how-rd-tax-credits-strengthen-a-life-science-companys-valuation\/#primaryimage"},"image":{"@id":"https:\/\/leyton.com\/us\/insights\/articles\/how-rd-tax-credits-strengthen-a-life-science-companys-valuation\/#primaryimage"},"thumbnailUrl":"https:\/\/leyton.com\/wp-content\/blogs.dir\/4\/files\/2026\/11\/USA-Website-inside-pictures-92.png","datePublished":"2026-11-05T14:19:55+00:00","dateModified":"2026-11-05T14:25:29+00:00","description":"Discover how cash-generating R&D tax credits extend runway, reduce dilution, and strengthen a life science company's valuation.","breadcrumb":{"@id":"https:\/\/leyton.com\/us\/insights\/articles\/how-rd-tax-credits-strengthen-a-life-science-companys-valuation\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/leyton.com\/us\/insights\/articles\/how-rd-tax-credits-strengthen-a-life-science-companys-valuation\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/leyton.com\/us\/insights\/articles\/how-rd-tax-credits-strengthen-a-life-science-companys-valuation\/#primaryimage","url":"https:\/\/leyton.com\/wp-content\/blogs.dir\/4\/files\/2026\/11\/USA-Website-inside-pictures-92.png","contentUrl":"https:\/\/leyton.com\/wp-content\/blogs.dir\/4\/files\/2026\/11\/USA-Website-inside-pictures-92.png","width":1920,"height":655,"caption":"valuation"},{"@type":"BreadcrumbList","@id":"https:\/\/leyton.com\/us\/insights\/articles\/how-rd-tax-credits-strengthen-a-life-science-companys-valuation\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/leyton.com\/us\/"},{"@type":"ListItem","position":2,"name":"How R&D Tax Credits Strengthen a Life Science Company’s Valuation"}]},{"@type":"WebSite","@id":"https:\/\/leyton.com\/#website","url":"https:\/\/leyton.com\/","name":"Leyton","description":"","publisher":{"@id":"https:\/\/leyton.com\/us\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/leyton.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/leyton.com\/us\/#organization","name":"Leyton","url":"https:\/\/leyton.com\/us\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/leyton.com\/us\/#\/schema\/logo\/image\/","url":"https:\/\/leyton.com\/wp-content\/blogs.dir\/4\/files\/2026\/01\/logo.svg","contentUrl":"https:\/\/leyton.com\/wp-content\/blogs.dir\/4\/files\/2026\/01\/logo.svg","width":108,"height":44,"caption":"Leyton"},"image":{"@id":"https:\/\/leyton.com\/us\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/leyton.com\/us\/wp-json\/wp\/v2\/article\/8852","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/leyton.com\/us\/wp-json\/wp\/v2\/article"}],"about":[{"href":"https:\/\/leyton.com\/us\/wp-json\/wp\/v2\/types\/article"}],"author":[{"embeddable":true,"href":"https:\/\/leyton.com\/us\/wp-json\/wp\/v2\/users\/72"}],"replies":[{"embeddable":true,"href":"https:\/\/leyton.com\/us\/wp-json\/wp\/v2\/comments?post=8852"}],"version-history":[{"count":6,"href":"https:\/\/leyton.com\/us\/wp-json\/wp\/v2\/article\/8852\/revisions"}],"predecessor-version":[{"id":8860,"href":"https:\/\/leyton.com\/us\/wp-json\/wp\/v2\/article\/8852\/revisions\/8860"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/leyton.com\/us\/wp-json\/wp\/v2\/media\/8855"}],"wp:attachment":[{"href":"https:\/\/leyton.com\/us\/wp-json\/wp\/v2\/media?parent=8852"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/leyton.com\/us\/wp-json\/wp\/v2\/categories?post=8852"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/leyton.com\/us\/wp-json\/wp\/v2\/tags?post=8852"},{"taxonomy":"expertise","embeddable":true,"href":"https:\/\/leyton.com\/us\/wp-json\/wp\/v2\/expertise?post=8852"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}